WO2000010610A3 - Drug targeting - Google Patents

Drug targeting Download PDF

Info

Publication number
WO2000010610A3
WO2000010610A3 PCT/GB1999/002606 GB9902606W WO0010610A3 WO 2000010610 A3 WO2000010610 A3 WO 2000010610A3 GB 9902606 W GB9902606 W GB 9902606W WO 0010610 A3 WO0010610 A3 WO 0010610A3
Authority
WO
WIPO (PCT)
Prior art keywords
ulcers
psoriasis
disclosed
reperfusion injury
bioreductive
Prior art date
Application number
PCT/GB1999/002606
Other languages
French (fr)
Other versions
WO2000010610A2 (en
Inventor
Ged Di Adams
David Blake
Declan Naughton
Ian Stratford
Original Assignee
Theramark Limited
Adams Margaret Lf
David Blake
Declan Naughton
Ian Stratford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818027.6A external-priority patent/GB9818027D0/en
Priority claimed from GBGB9818156.3A external-priority patent/GB9818156D0/en
Application filed by Theramark Limited, Adams Margaret Lf, David Blake, Declan Naughton, Ian Stratford filed Critical Theramark Limited
Priority to AU54296/99A priority Critical patent/AU5429699A/en
Publication of WO2000010610A2 publication Critical patent/WO2000010610A2/en
Publication of WO2000010610A3 publication Critical patent/WO2000010610A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of a bioreductive conjugate comprised of a non-cytoxic bioreductive moiety having linked thereto at least one therapeutic agent, and salts thereof, is disclosed for the healing of wounds and the treatment of fibrotic disorders, ulcerative colitis, inflammatory bowel disease, epilepsy, cardiovascular reperfusion injury, cerebral reperfusion injury, hypertensions, cystic fibrosis, psoriasis, para-psoriasis, peptic ulcers, gastric ulcers, duodenal ulcers, diabetic ulcers dementia, oncology, Aids, rheumatoid arthritis, diabetes, and ischemia. Various specific conjugates for treating these conditions are also disclosed.
PCT/GB1999/002606 1998-08-19 1999-08-19 Drug targeting WO2000010610A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54296/99A AU5429699A (en) 1998-08-19 1999-08-19 Drug targeting

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9818027.6A GB9818027D0 (en) 1998-08-19 1998-08-19 Drug targeting I
GB9818027.6 1998-08-19
GB9818156.3 1998-08-20
GBGB9818156.3A GB9818156D0 (en) 1998-08-20 1998-08-20 Drug targeting

Publications (2)

Publication Number Publication Date
WO2000010610A2 WO2000010610A2 (en) 2000-03-02
WO2000010610A3 true WO2000010610A3 (en) 2000-06-02

Family

ID=26314233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002606 WO2000010610A2 (en) 1998-08-19 1999-08-19 Drug targeting

Country Status (2)

Country Link
AU (1) AU5429699A (en)
WO (1) WO2000010610A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
CA2430010A1 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
CA2511582C (en) * 2003-02-06 2012-01-24 Dompe S.P.A. 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
DE102004025535A1 (en) * 2004-05-25 2005-12-22 Bayer Healthcare Ag Combination of salts of o-acetylsalicylic acid and alpha-glucosidase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035701A1 (en) * 1997-02-11 1998-08-20 Theramark Limited Drug targeting

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035701A1 (en) * 1997-02-11 1998-08-20 Theramark Limited Drug targeting

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BEALL, HOWARD D. ET AL: "Indolequinone Antitumor Agents: Correlation between Quinone Structure, Rate of Metabolism by Recombinant Human NAD(P)H:Quinone Oxidoreductase, and in Vitro Cytotoxicity", J. MED. CHEM. (1998), 41(24), 4755-4766, XP002131258 *
BERGLUND R A: "BIOREDUCTIVE HETEROSUBSTITUTED QUINONE ANTITUMOR DRUG DELIVERY AGENTS", DISSABS, XP002052358 *
CHIKHALE P ET AL: "TUMOR TARGETED PRODRUGS: REDOX-ACTIVATION OF CONFORMATIONALLY CONSTRAINED, BIOREDUCTIVE MELPHALAN PRODRUGS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. 38, 1997, pages 432, XP002052354 *
EVERETT S A ET AL: "Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 9, no. 9, 3 May 1999 (1999-05-03), pages 1267 - 1272, XP004163956, ISSN: 0960-894X *
JAFFAR M ET AL: "Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 9, no. 1, January 1999 (1999-01-01), pages 113 - 118, XP004154788, ISSN: 0960-894X *
JAFFAR M. ET AL: "Bioreductive drugs: Selectivity towards hypoxic tissue.", EXPERT OPINION ON THERAPEUTIC PATENTS, (1999) 9/10 (1371-1380)., XP002131797 *
NAYLOR M.A. ET AL: "Indolequinone antitumor agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia - selective cytotoxicity in vitro.", JOURNAL OF MEDICINAL CHEMISTRY, (1998) 41/15 (2720-2731)., XP002131259 *
NAYLOR, MATTHEW A. ET AL: "2-Cyclopropylindoloquinones and Their Analogs As Bioreductively Activated Antitumor Agents: Structure-Activity in Vitro and Efficacy in Vivo", J. MED. CHEM. (1997), 40(15), 2335-2346, XP002131260 *
PARVEEN I ET AL: "2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 9, no. 14, 19 July 1999 (1999-07-19), pages 2031 - 2036, XP004171631, ISSN: 0960-894X *
RAUTH A.M. ET AL: "Bioreductive therapies: An overview of drugs and their mechanisms of action.", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, (1998) 42/4 (755-762)., XP002131257 *

Also Published As

Publication number Publication date
AU5429699A (en) 2000-03-14
WO2000010610A2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
EP0699072A4 (en) Iron-binding polymers for oral administration
CA2164866A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
CA2259012A1 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
NO20001001D0 (en) Poly (ADP-ribose) polymerase ("PARP") inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue injuries
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
WO1998046258A3 (en) Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
CA2179521A1 (en) 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps
CA2180011A1 (en) Botulinum toxins for treating sweating
PT1147110E (en) PIRAZINE (AZA) -INDOL DERIVATIVES
MY119375A (en) Treatment of tinnitus using neuroprotective agents
EP0244083A3 (en) Amino acid derivatives
WO2000010610A3 (en) Drug targeting
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
GB9310095D0 (en) Therapeutic compounds
EP2286826A3 (en) Treatment of tumor metastase and cancer
AU2727701A (en) Nitroglycerin ointment for treatment of pain associated with anal disease
AU4175893A (en) Treatment of inflammatory bowel disease
AU2693697A (en) Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin
CA2362888A1 (en) Use of r-aryl propionic acids for producing medicaments to treat diseases in humans and animals, whereby said diseases can be therapeutically influenced by inhibiting the activation of nf-kb
EP0437929A3 (en) Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease
AU4442389A (en) 1,2,3,4-tetrahydro-1,9-acridinediamines, a process for their preparation and their use as medicaments
GEP20043224B (en) Substituted Benzolactam Compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase